TCT 2017: Cardiovascular Research Foundation announces late-breaking trials and first-report investigations

68

The Cardiovascular Research Foundation (CRF) has release details of the 12 late-breaking trials and 16 first report investigations that are to be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 scientific symposium (29 October–2 November, Denver, USA).

Both the late-breaking clinical trials and first report investigations will be presented in the main arena (see the agenda for full details). They are as follows:

30 October (Monday)

Late-breaking trials

  • CULPRIT-SHOCK: A randomised Trial of multivessel PCI in cardiogenic shock
  • EXCEL QOL: Quality of life after PCI vs CABG in left main coronary artery disease
  • DKCRUSH-V: A randomised trial of double kissing crush vs provisional stenting for treatment of distal left main bifurcation lesions

First report investigations

  • HREVS: A randomised trial of PCI vs CABG vs hybrid revascularization in patients with coronary artery disease
  • HARMONEE: A randomised trial of a bioabsorbable polymer-based DES with a luminal CD34+ antibody coating vs a durable polymer-based DES in patients with coronary artery disease
  • DARE: A randomised trial of a drug-eluting balloon vs a metallic DES in patients with coronary artery in-stent restenosis
  • VAMPIRE 3: A randomised trial of distal filter protection during PCI of high-risk plaque

31 October (Tuesday)

Late-breaking trials

  • ABSORB IV: 30-day outcomes from a randomised trial of a bioresorbable scaffold vs a metallic DES in patients with coronary artery disease
  • ABSORB III: 3-year outcomes from a randomised trial of a bioresorbable scaffold vs a metallic DES in patients with coronary artery disease
  • PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in intermediate-risk patients with aortic stenosis

First report investigations

  • ABSORB II: 4-year outcomes from a randomised trial of a bioresorbable scaffold vs a metallic DES in patients with coronary artery disease
  • CrossBoss First: A randomised trial of antegrade dissection and re-entry vs standard wire escalation for crossing coronary artery chronic total occlusions
  • REVASC: A randomised trial to assess recovery of left ventricular function after PCI of coronary artery chronic total occlusions
  • FAVOR II China: Diagnostic accuracy of the angiographic quantitative flow ratio in patients with coronary artery disease
  • FAVOR II Europe Japan: Diagnostic accuracy of the angiographic quantitative flow ratio in patients with coronary artery disease

1 November (Wednesday)

Late-breaking trials

  • SENIOR: A randomised trial of a bioabsorbable polymer-based Metallic DES vs a BMS with short DAPT in patients with coronary artery disease older than 75 years
  • DAPT STEMI: A randomised trial of 6-month vs 12-month DAPT after DES implantation in STEMI
  • REDUCE: A randomised trial of 3-month vs 12-month DAPT after implantation of a bioabsorbable polymer-based metallic DES with a luminal CD34+ antibody coating in patients with ACS

First report investigations

  • MITRAL: 30-day outcomes of transcatheter MV replacement in patients with severe mitral valve disease secondary to mitral annular calcification or failed annuloplasty rings
  • INTREPID: 30-day outcomes of transcatheter MV replacement in patients with severe mitral regurgitation
  • TENDYNE: 1-year outcomes of transcatheter MV replacement in patients with severe mitral regurgitation
  • TRACER: 6-month outcomes of transcatheter MV Neochordal repair in patients with severe primary mitral regurgitation
  • MAVERIC: 6-month outcomes of transcatheter MV repair in patients with severe secondary mitral regurgitation

2 November (Thursday)

Late-breaking trials    

  • PREVAIL: 5-year outcomes from a randomised trial of left atrial appendage closure vs medical therapy in patients with non-valvular atrial fibrillation
  • ORBITA: A randomised, sham-controlled trial of PCI in patients with coronary artery disease
  • FAME 2: 3-year clinical and cost-effectiveness outcomes of FFR-guided PCI in patients with coronary artery disease

First report investigations

  • TRI-REPAIR: 30-day outcomes of transcatheter TV repair in patients with severe secondary tricuspid regurgitation
  • FORMA: 30-day outcomes of transcatheter TV repair in patients with severe secondary tricuspid regurgitation

LEAVE A REPLY